SCHEMBL298638

SCHEMBL298638

Cc1ccc(C(=O)CN2C=CCC(c3cc(CCC4CCCCC4)[nH]n3)=C2)s1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
BRS3 P32247 1/20 0.31
PLK4 O00444 1/20 0.30
PDPK1 O15530 1/20 0.30
DAPK3 O43293 1/20 0.30
PRKD3 O94806 1/20 0.30
MAP4K4 O95819 1/20 0.30
CHEK2 O96017 1/20 0.30
CDK1 P06493 1/20 0.30
RET P07949 1/20 0.30
PIM1 P11309 1/20 0.30
FGFR1 P11362 1/20 0.30
FLT1 P17948 1/20 0.30
MARK3 P27448 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298106 0.79 RAB9A (0.31) LMNAPOLBALDH1A1GAA
SCHEMBL660037 0.71 NPC1 (0.36) LMNAL3MBTL1ALDH1A1MAPK1KDR
SCHEMBL28797880 0.70 DAO (0.33)
SCHEMBL27854972 0.68 BRS3 (0.33) BRS3
SCHEMBL660157 0.67 HTT (0.33) RECQLALDH1A1
SCHEMBL660291 0.65 KMT2A (0.38) LMNAPOLBL3MBTL1ALDH1A1HPGD
SCHEMBL287276 0.63 ALDH1A1 (0.35) L3MBTL1ALDH1A1HPGD
SCHEMBL7798097 0.62 KMT2A (0.36) LMNAPOLBL3MBTL1ALDH1A1HPGD
SCHEMBL659354 0.60 ALDH1A1 (0.33) POLBALDH1A1HPGDMAPK1GAA
SCHEMBL279616 0.58 RAB9A (0.49) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT LMNA 123/4885POLB 2267/4885RECQL 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.